The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Pfizer
Expert Testimony - Roche
Management of checkpoint inhibitor toxicity and survival in patients with advanced melanoma.
 
Olivier Jules van Not
No Relationships to Disclose
 
Rik Jasper Verheijden
No Relationships to Disclose
 
Alfonsus Johannes Maria van den Eertwegh
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Ipsen; Merck; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - BMS; Roche; Sanofi
 
John B. A. G. Haanen
Stock and Other Ownership Interests - Neogene Therapeutics
Consulting or Advisory Role - Achilles Therapeutics (Inst); bioNTech (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Novartis (Inst); Pfizer (Inst); POEM Health (Inst); Roche/Genentech (Inst); Sanofi (Inst); T-Knife (Inst); Third Rock Ventures (Inst)
Research Funding - Amgen (Inst); Asher Biotherapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Christian U. Blank
Stock and Other Ownership Interests - Immagene
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - 4SC (Inst); Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - WO 2021/177822 A1
Expert Testimony - Freshfields Bruckhaus Deringer
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Maureen J.B. Aarts
Research Funding - Pfizer (Inst)
 
Franchette Van Den Berkmortel
No Relationships to Disclose
 
Jan Willem de Groot
Consulting or Advisory Role - Bristol-Myers Squibb; Pierre Fabre; SERVIER
 
Geke Hospers
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Seerave Foundation (Inst)
 
Ellen Kapiteijn
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); Ipsen (Inst); Lilly (Inst); Novartis (Inst); Pierre Fabre (Inst)
Research Funding - BMS (Inst); Pierre Fabre (Inst)
 
Melissa Melanie de Meza
No Relationships to Disclose
 
Djura Piersma
Consulting or Advisory Role - Novartis (Inst); Pierre Fabre (Inst)
 
Rozemarijn Van Rijn
No Relationships to Disclose
 
Marion Stevense - den Boer
No Relationships to Disclose
 
Astrid Aplonia Maria Van Der Veldt
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Novartis; Roche; Roche
 
Gerard Vreugdenhil
No Relationships to Disclose
 
Marye J. Boers-Sonderen
No Relationships to Disclose
 
Willeke Blokx
No Relationships to Disclose
 
Michel W.J.M. Wouters
No Relationships to Disclose
 
Karijn Suijkerbuijk
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst)
Speakers' Bureau - Novartis (Inst); Roche (Inst)